NEW YORK, Oct. 28 (GenomeWeb News) - Benitec said today that it has granted a worldwide non-exclusive license to Artemis Pharmaceuticals for use of its proprietary ddRNAi technology in transgenic mouse and rat model development.
Benitec said it will receive an up-front license fee and ongoing royalties, but did not disclose additional financial details.
Artemis will use the ddRNAi technology to add in vivo gene knock-down capabilities to its ArteMice rodent model platform.
Benitec said that Artemis - a subsidiary of Exelixis based in
In August, Benitec licensed the technology to GenScript and Ambion under patent infringement settlements related to its ddRNAi patent estate. A third patent infringement case, with Nucleonics, is still pending, following Nucleonics' requests to both the US and Australian patent authorities to re-examine Benitec's patents.